Jane Street Group, LLC Revance Therapeutics, Inc. Transaction History

Jane Street Group, LLC

$444 Billion
Q4 2024

A detailed history of Jane Street Group, LLC transactions in Revance Therapeutics, Inc. stock. As of the latest transaction made, Jane Street Group, LLC holds 113,150 shares of RVNC stock, worth $290,795. This represents 0.0% of its overall portfolio holdings.

Number of Shares

113,150

Previous 568,654 80.1%

Holding current value

$290,795

Previous $1.46 Million 80.15%

% of portfolio

0.0%

Previous 0.0%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	SELL	N/A	-455,504 Reduced 80.1%	113,150 $290,000
Q3 2024 Nov 14, 2024	BUY	$2.57 - $2.57 $1.04 Million - $1.04 Million	404,741 Added 246.92%	568,654 $1.46 Million
Q2 2024 Aug 14, 2024	BUY	$2.34 - $4.73 $56,188 - $113,576	24,012 Added 17.16%	163,913 $421,000
Q1 2024 May 15, 2024	BUY	$4.65 - $9.31 $384,629 - $770,085	82,716 Added 144.65%	139,901 $688,000
Q4 2023 Feb 14, 2024	SELL	$5.81 - $11.2 $521,720 - $1.01 Million	-89,797 Reduced 61.09%	57,185 $502,000
Q3 2023 Nov 14, 2023	BUY	$11.47 - $25.07 $401,392 - $877,324	34,995 Added 31.25%	146,982 $1.69 Million
Q2 2023 Aug 14, 2023	SELL	$24.7 - $37.61 $4.02 Million - $6.12 Million	-162,812 Reduced 59.25%	111,987 $2.83 Million
Q1 2023 May 15, 2023	BUY	$18.36 - $35.27 $4.58 Million - $8.79 Million	249,255 Added 975.79%	274,799 $8.85 Million
Q4 2022 Feb 14, 2023	SELL	$18.32 - $30.66 $4.06 Million - $6.79 Million	-221,521 Reduced 89.66%	25,544 $471,000
Q3 2022 Nov 14, 2022	BUY	$14.33 - $28.47 $2.96 Million - $5.88 Million	206,702 Added 512.11%	247,065 $6.67 Million
Q2 2022 Aug 16, 2022	SELL	$11.52 - $20.4 $690,888 - $1.22 Million	-59,973 Reduced 59.77%	40,363 $558,000
Q1 2022 May 17, 2022	BUY	$12.36 - $20.31 $873,060 - $1.43 Million	70,636 Added 237.83%	100,336 $1.96 Million
Q4 2021 Feb 15, 2022	SELL	$12.46 - $27.87 $78,012 - $174,494	-6,261 Reduced 17.41%	29,700 $485,000
Q3 2021 Nov 16, 2021	SELL	$25.78 - $33.21 $23,047 - $29,689	-894 Reduced 2.43%	35,961 $1 Million
Q4 2020 Feb 17, 2021	BUY	$23.41 - $28.34 $300,186 - $363,403	12,823 Added 53.36%	36,855 $1.05 Million
Q3 2020 Nov 17, 2020	BUY	$23.23 - $34.3 $558,263 - $824,297	24,032 New	24,032 $605,000
Q2 2019 Aug 15, 2019	SELL	$10.67 - $15.49 $213,709 - $310,249	-20,029 Closed	0 $0
Q1 2019 May 16, 2019	BUY	$15.4 - $20.39 $99,191 - $131,331	6,441 Added 47.4%	20,029 $316,000
Q4 2018 Feb 15, 2019	BUY	$18.06 - $24.96 $245,399 - $339,156	13,588 New	13,588 $274,000
Q1 2018 May 15, 2018	SELL	$29.15 - $37.4 $558,863 - $717,032	-19,172 Closed	0 $0
Q4 2017 Feb 15, 2018	BUY	$24.55 - $36.3 $470,672 - $695,943	19,172	19,172 $685,000

Others Institutions Holding RVNC

# of Institutions

208

Shares Held

80.9M

Call Options Held

2.26M

Put Options Held

5.48M

View Full List

About Revance Therapeutics, Inc.

Ticker RVNC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,305,696
Market Cap $212M
Description
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...

More about RVNC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jane Street Group, LLC with notifications on news.

Account

Jane Street Group, LLC Revance Therapeutics, Inc. Transaction History